Research article · 30 Jul 2026
Conference abstractPublished 24 Aug 2024
Immune Pathways and Innovative Prospects in the Treatment of Vitiligo
Master degree, China
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objective: The primary objective of this randomized controlled trial (RCT) is to assess the efficacy and safety of Ritlecitinib, a Janus kinase (JAK) inhibitor, in treating patients with non-segmental vitiligo. Methods and Materials: The study enrolled 90 participants diagnosed with non-segmental vitiligo, randomized into two groups: 45 received Ritlecitinib, and 45 were given a placebo. The trial duration was 24 weeks, with a follow-up period of 12 weeks. Primary efficacy endpoints were the Vitiligo Area Scoring Index (VASI) and repigmentation percentage. Secondary endpoints included safety profiles, patient quality of life (assessed using DLQI - Dermatology Life Quality Index), and immunological markers relevant to vitiligo pathogenesis. Results: At the conclusion of 24 weeks, the Ritlecitinib group demonstrated significant improvements compared to the placebo group. Key findings include: Mean VASI reduction: 47.6% in the Ritlecitinib group vs. 15.2% in the placebo group (p<0.001). Patients achieving 50% repigmentation: 39.3% in the Ritlecitinib group compared to 9.3% in the placebo group (p<0.001). DLQI score improvements were more pronounced in the Ritlecitinib group (average reduction of 18 points) compared to the placebo (average reduction of 6 points). Immunological analysis indicated a significant reduction in circulating autoantibodies and an increase in regulatory T-cells in the Ritlecitinib group. Adverse events were mild to moderate in severity, with the most common being mild gastrointestinal discomfort and headache.
Subjects
DermatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical & Experimental Dermatology Research.
Commentary · 30 Jul 2026
Breaking the Stigma Around Psoriasis: A Broader View of Chronic Skin Disease
Perspective · 28 Jul 2026
Acne as More Than a Cosmetic Concern: A Personal and Medical Perspective
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Experimental Dermatology Research
- SubjectDermatology
- BylineArticles whose byline prints “Rui Yuan”
